Brind.

BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.

3 reports, 3 independent Updated Sep 8

Gone quiet

Reports: 3
Developments: 3
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

BioVie is seeking pivotal milestones for its lead drug candidate targeting neuroinflammation pathways for Parkinson's disease.

Who's involved

What this event is mainly about

FDA Biovie

How it developed

Newest first. Tap a step to see who reported it.

Sep 8BioVie requested a meeting with the FDA to advance drug development.1 source
- proactiveinvestors.com
Aug 14Biovie's bezisterim is entering Phase 2 trials and secured $21.5M in government funding for Parkinson's.1 source
- californiatelegraph.com
May 27BioVie seeks pivotal milestones for its lead candidate targeting neuroinflammation pathways for Parkinson's disease.1 source
- manilatimes.net

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Biovie
French company founded in 2007, specializing in online sales of organic, raw, and living foods, committed to education on healthy eating.

Nothing else this week.

Coverage

Newest first; wire copies grouped